Retatrutide (often referred to as “Reta” or “Reta Peptide”) is an investigational triple-hormone receptor agonist (“triple-G”) developed by Eli Lilly that is currently undergoing Phase 3 clinical trials for the treatment of obesity, type 2 diabetes, and related metabolic conditions.